Recent Updates
Recently added Catalysts
IMRX Positive Sentiment

Publication in Cancer Research Details Atebimetinib’s Broad, Durable Preclinical Activity and Favorable Tolerability Across RAS- and RAF-Mutant Tumors via Deep Cyclic Inhibition

Tuesday, July 21, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Atebimetinib has shown significant antitumor activity in preclinical studies targeting KRAS, NRAS, and BRAF mutations. The drug effectively inhibits RAF-mediated bypass signaling, which has limited the effectiveness of other MEK inhibitors. Its favorable tolerability profile was also noted, making it a promising candidate for further development in treating various cancers.
Price reaction · baseline $4.46 (2026-07-21 close) · hit after-hours · 2 other IMRX headline(s) in the window, move may be shared
day 0 close
+0.2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Atebimetinib demonstrated broad antitumor activity across various mutant models.
  • The drug showed favorable tolerability in preclinical studies.
  • It effectively resists RAF-mediated bypass signaling, a common issue with other MEK inhibitors.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+41%
120-day peak, hindsight
Typical move
11.4%
average across 8 past catalysts
Cash runway
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 Monotherapy
Phase 1 · Advanced Solid Tumor

Full Press Release Details

- Atebimetinib showed broad antitumor activity across KRAS-, NRAS-, and BRAF-mutant models, including colorectal, lung, and melanoma, by resisting the RAF-mediated bypass signaling that has constrained other MEK inhibitors - - In head-to-head in vivo studies, atebimetinib produced deeper, more

Frequently Asked Questions

What types of tumors does Atebimetinib target?

Atebimetinib targets KRAS-, NRAS-, and BRAF-mutant tumors, including colorectal, lung, and melanoma.

How does Atebimetinib compare to other MEK inhibitors?

Atebimetinib resists RAF-mediated bypass signaling, which limits the effectiveness of other MEK inhibitors.

What was noted about Atebimetinib's tolerability?

Atebimetinib demonstrated favorable tolerability in preclinical studies.

What kind of studies were conducted on Atebimetinib?

Head-to-head in vivo studies were conducted to assess Atebimetinib's antitumor activity.

ShareAdd on Google
Tags: IMRX Viatris Investor Conferences Healthcare Atebimetinib KRAS NRAS BRAF cancer research
Last updated: Jul 21, 2026

Biotech snapshot

Cash runway
$202M liquidity · $6M/mo burn
~36 mo
Minimal dilution risk
Lead asset
IMM-1-104 MonotherapyPhase 1
Advanced Solid Tumor →

Catalyst track record

+41%
best trade around IMRX's most recent catalyst

Peak hindsight return over a 120-day window, across 8 tracked FDA/PDUFA catalysts for IMRX.

See every catalyst's timing & PoA →